Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Pfizer Inc. (NYSE:PFE) is among the 13 Most Undervalued S&P 500 Stocks to Invest In. On February 27, 2026, Pfizer Inc.

USA: A recent systematic review and meta-analysis published in Diabetes Research and Clinical Practice has unveiled compelling evidence that type 1 diabetes may be a significant and ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

Ten years ago, a discussion in Milan set a demanding project in motion. In a meeting between a biologist and a urologist, one ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

Data from the IMvigor011 phase 3 study shows that adjuvant atezolizumab (Tecentriq) significantly boosts the reduction and clearance of circulating tumor DNA (ctDNA). Presented at ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...